{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"100.00","upperLimit":"100.00","value":"100.00"},{"groupId":"OG001","lowerLimit":"100.00","upperLimit":"100.00","value":"100.00"},{"groupId":"OG002","lowerLimit":"100.00","upperLimit":"100.00","value":"100.00"},{"groupId":"OG003","lowerLimit":"100.00","upperLimit":"100.00","value":"100.00"},{"groupId":"OG004","lowerLimit":"100.00","upperLimit":"100.00","value":"100.00"},{"groupId":"OG005","lowerLimit":"100.00","upperLimit":"100.00","value":"100.00"},{"groupId":"OG006","lowerLimit":"100.00","upperLimit":"100.00","value":"100.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"41"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"6"}],"units":"Participants"}],"description":"Defined as disease recurrence at lymph nodes regional to the primary disease site, with or without local failure but without distant failure. The relative risk of specific failure types will be estimated and compared descriptively using the Cox proportional hazard model. Data were obtained from institutional reported data.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose-Finding Level 1 CR:\n\nAdult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2","id":"OG000","title":"Dose-Finding Level 1 CR"},{"description":"Dose-Finding Level 1 RT:\n\nAdult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2","id":"OG001","title":"Dose-Finding Level 1 RT"},{"description":"Dose-Finding Level 2 RT:\n\nAdult: Pazopanib 800 mg; Pediatric: Pazopanib 450 mg/m2","id":"OG002","title":"Dose-Finding Level 2 RT"},{"description":"Regimen A: Chemoradiation plus pazopanib","id":"OG003","title":"Regimen A"},{"description":"Regimen B: Chemoradiation alone","id":"OG004","title":"Regimen B"},{"description":"Regimen C: Radiation therapy plus pazopanib","id":"OG005","title":"Regimen C"},{"description":"Regimen D: Radiation therapy alone","id":"OG006","title":"Regimen D"}],"paramType":"NUMBER","populationDescription":"Patients deemed ineligible in the original cohort are excluded. An additional five (5) patients are excluded in this 5-year analysis as they were deemed ineligible post the initial submission and publication.","reportingStatus":"POSTED","timeFrame":"From enrollment to up to 60 months","title":"Percentage of Patients Regional Failure Free at 5 Years Following Study Entry","type":"SECONDARY","unitOfMeasure":"percentage of participants"}